0001558370-23-010931.txt : 20230609 0001558370-23-010931.hdr.sgml : 20230609 20230609060106 ACCESSION NUMBER: 0001558370-23-010931 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230609 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230609 DATE AS OF CHANGE: 20230609 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Editas Medicine, Inc. CENTRAL INDEX KEY: 0001650664 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464097528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37687 FILM NUMBER: 231003776 BUSINESS ADDRESS: STREET 1: 11 HURLEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-401-9000 MAIL ADDRESS: STREET 1: 11 HURLEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02141 8-K 1 edit-20230609x8k.htm 8-K
0001650664false00016506642023-06-092023-06-09

​

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2023

Editas Medicine, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-37687

46-4097528

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

​

11 Hurley Street
Cambridge, Massachusetts

02141

(Address of Principal Executive Offices)

(Zip Code)

​

Registrant’s telephone number, including area code: (617) 401-9000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

​

​

​

Common Stock, $0.0001 par value per share

EDIT

The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

​

​

 

​

​

Item 7.01.Regulation FD Disclosure.

On June 9, 2023, Editas Medicine, Inc. (the “Company”) issued a press release titled “Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial.” A copy of the press release is furnished as Exhibit 99.1 hereto.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01.Other Events.

On June 9, 2023, the Company announced initial safety and efficacy data from the first four patients with sickle cell disease (“SCD”) treated with EDIT-301 in the Company’s ongoing RUBY trial and from the first transfusion-dependent beta thalassemia (“TDT”) patient treated in the EdiTHAL trial.

In the RUBY trial, Patients 1 (male) and 2 (female) reached normal hemoglobin levels five months post-treatment with EDIT-301 and maintained a normal hemoglobin level at 10- and six-month follow-up, respectively. Each of these patients had fetal hemoglobin levels of greater than 40% persist during the same time frame.

Patient 1’s total hemoglobin returned to a normal physiological level of 16.4g/dL (male normal range: 13.6–18.0 g/dL) at five months after infusion of EDIT-301 and has been maintained at this level at 10-month follow-up. In addition, Patient 1’s fetal hemoglobin fraction increased from 5% at baseline to 45.4% five months after treatment with EDIT-301 and 43.4% at the 10-month follow-up. Patient 2’s total hemoglobin reached a normal physiological level of 12.7 g/dL (female normal range: 12.0–16.0 g/dL) at five months after infusion of EDIT-301 and fetal hemoglobin increased from 10.8% at baseline to 51.3% at six-month follow-up.

Patients 3 (female) and 4 (male) in the RUBY trial saw increases in total hemoglobin and fetal hemoglobin fractions at three and two months of follow up, respectively, that followed similar trajectories as those seen in the first two patients at the same timepoints. All four treated RUBY patients were free of vaso-occlusive events following infusion with EDIT-301.

In the EdiTHAL trial, the first patient (male) had successful neutrophil and platelet engraftment within 30 days of infusion, and, at one and a half months post-infusion, the patient’s response resembled that of the first four RUBY patients, achieving a fetal hemoglobin fraction of 34.9% representing 4 g/dL of total hemoglobin.

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan, the regimen that is necessary for current gene editing therapies for SCD and TDT, and autologous hematopoietic stem cell transplant by the four patients in the RUBY trial and the first patient in the EdiTHAL trial. After EDIT-301 infusion, no serious adverse events occurred, and no adverse events reported were related to treatment with EDIT-301.

Item 9.01.Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No.

 

Description

99.1

 

Press Release dated June 9, 2023

104

​

Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

 

    

EDITAS MEDICINE, INC.

 

​

 

Date:

June 9, 2023

​

By:

/s/ Gilmore O'Neill

 

 

​

 

Gilmore O'Neill
President and Chief Executive Officer

​

​

​

​

 EX-99.1 2 edit-20230609xex99d1.htm EX-99.1

Graphic

Exhibit 99.1

​

Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the
First Four Patients Treated in the RUBY Trial and the First Patient Treated in the
EdiTHAL Trial

​

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative
conditioning with busulfan and autologous hematopoietic stem cell transplant

​

First two RUBY patients achieved normal levels of total hemoglobin and fetal hemoglobin of
>40% at 5 months and maintained these levels after 10 and 6 months of follow up

​

All five patients treated with EDIT-301 successfully engrafted and all four RUBY patients treated
are free of vaso-occlusive events since infusion

​

RUBY clinical data to be presented at the European Hematology Association (EHA) Hybrid
Congress on Saturday, June 10, at 5:30 p.m. CET/11:30 a.m. ET

​

Company to host a virtual event on the RUBY and EdiTHAL data on Monday, June 12 at 8:00
a.m. ET

​

CAMBRIDGE, Mass., June 9, 2023 – Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced positive initial safety and efficacy data from the first four patients with sickle cell disease (SCD) treated with EDIT-301 in the RUBY trial and from the first transfusion-dependent beta thalassemia patient treated in the EdiTHAL trial.

​

The RUBY trial data will be presented in an oral presentation at European Hematology Association (EHA) Hybrid Congress in Frankfurt, Germany, and via live stream on Saturday, June 10, at 5:30 p.m. CEST/11:30 a.m. EDT. Editas Medicine will present the RUBY trial data and the EdiTHAL trial data on Monday, June 12, at 8 a.m. ET in a Company-sponsored webinar.

​

In the RUBY trial, Patients 1 and 2 reached normal hemoglobin levels five months post-treatment with EDIT-301, and both patients have maintained a normal hemoglobin level at ten- and six-month follow-up, respectively. Additionally, each of these patients has seen fetal hemoglobin levels of greater than 40% persist during the same time frame. Patients 3 and 4 in the RUBY trial saw increases in total hemoglobin and fetal hemoglobin at three and two months of follow up, respectively, that follow similar trajectories as those seen in the first two patients. All four treated RUBY patients are also free of vaso-occlusive events (VOEs) since infusion.

​

In the EdiTHAL trial, the first patient demonstrated successful neutrophil and platelet engraftment, and, at one and a half months post-infusion, the patient’s response resembles that of the first four RUBY patients.

​

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant by the four

​

​

​

patients in the RUBY trial and the first patient in the EdiTHAL trial. After EDIT-301 infusion, no serious adverse events occurred, and no adverse events reported were related to treatment with EDIT-301.

​

RUBY Trial

Safety

All treated patients demonstrated successful neutrophil and platelet engraftment. No serious adverse events (SAEs) were reported after EDIT-301 infusion, and no adverse events (AEs) related to EDIT-301 treatment have been observed. All four treated patients in the RUBY trial are free from vaso-occlusive events since infusion with EDIT-301, with 2-10 months follow-up.

​

Efficacy

Patient 1 (male) has had 10 months of follow-up. Patient 1’s total hemoglobin returned to normal physiological level of 16.4g/dL (male normal range: 13.6–18.0 g/dL) at five months after infusion of EDIT-301 and has been maintained at this level at the 10-month follow-up. In addition, Patient 1’s fetal hemoglobin fraction increased from 5% at baseline to 45.4% five months after treatment with EDIT-301 and 43.4% at the 10-month follow-up.

​

Patient 2 (female) has had 6 months of follow-up. Patient 2’s total hemoglobin reached normal physiological level of 12.7 g/dL (female normal range: 12.0–16.0 g/dL) at five months after infusion of EDIT-301 and fetal hemoglobin increased from 10.8% at baseline to 51.3% at the 6-month follow-up.

​

Patient 3 (female) and Patient 4 (male) have had three and two months of follow-up, respectively. Increases in total hemoglobin and fetal hemoglobin fractions for Patient’s 3 and 4 are following similar trajectories as seen in Patients 1 and 2 at the same timepoints.

​

EdiTHAL Trial

Safety

The first treated patient (male) in the EdiTHAL trial has had 1.5 months of follow-up. Patient 1 had successful neutrophil and platelet engraftment within 30 days of EDIT-301 infusion, and the safety profile has been consistent with that of myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant. No serious adverse events occurred after EDIT-301 infusion, and no adverse events reported were related to treatment with EDIT-301.

​

Efficacy

The first EdiTHAL patient’s experience with EDIT-301 resembles that of the first four RUBY patients, achieving a fetal hemoglobin fraction of 34.9% representing 4 g/dL of total hemoglobin at 1.5 months post-treatment.

​

“These promising data support our belief that EDIT-301 can be a clinically differentiated, one-time, durable medicine that can provide life changing clinical benefits to patients with sickle cell disease and beta thalassemia long term, specifically driving early and robust correction of anemia

​

​

​

and sustained increases in fetal hemoglobin,” said Baisong Mei, MD, Ph.D., Senior Vice President and Chief Medical Officer, Editas Medicine. “I would like to thank the clinical trial participants, their families, clinicians, and colleagues at collaborating institutions that contribute to the RUBY and EdiTHAL trials. We remain on-track to dose 20 RUBY patients by year-end, and we look forward to sharing further RUBY and EdiTHAL clinical updates later this year.”

​

“I am encouraged by the results from the RUBY trial, which indicate this investigational gene editing treatment has been well-tolerated and efficacious in treated trial participants thus far. While we need to let the trial finish and enroll many other patients to understand the overall benefits and risks of this treatment, I am pleased to see transformative results at this stage in the study,” said Rabi Hanna, M.D., Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic Children’s.

​

EDIT-301 uses AsCas12a, a novel, proprietary, highly efficient, and specific gene editing nuclease, to edit the promoter regions of gamma globin gene 1 and 2 to increase the expression of HbF to mimic the naturally occurring mechanism of hereditary persistence of fetal hemoglobin to treat SCD. The RUBY trial marks the first time AsCas12a was used to successfully edit human cells in a clinical trial.

​

EHA Oral Presentation Details:

Title: EDIT-301 Shows Promising Preliminary Safety and Efficacy Results in the Phase I/II Clinical Trial (RUBY) of Patients with Severe Sickle Cell Disease Using Highly Specific and Efficient AsCas12a Enzyme

Presenting Author: Rabi Hanna, M.D., Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic Children’s, Cleveland, OH, United States

Date/Time: Saturday, June 10, 2023, 4:30 – 5:45 p.m. CEST/ 10:30 – 11:45 a.m. EDT

Location: Harmonie 1, Messe Frankfurt

Session: s437 Gene therapy and cellular immunotherapy – Clinical

​

Virtual Event Information

Editas Medicine will host a virtual event on Monday, June 12, at 8:00 a.m. ET to present the data for the RUBY and EdiTHAL trials. The live and archived webcast of the presentation will be accessible through this webcast link, or through the Events & Presentations page of the “Investors” section of the Company’s website.

​

EDIT-301 is currently being investigated in clinical studies in patients with severe sickle cell disease (RUBY trial, NCT04853576) and transfusion-dependent beta thalassemia (EDITHAL trial, NCT05444894). In addition to the clinical data update from the RUBY trial at EHA and in a Company-sponsored webinar, the Company expects to present a further clinical update from the RUBY and EdiTHAL trials by year-end.

​

​

​

About Sickle Cell Disease

Sickle cell disease is an inherited blood disorder caused by a mutation in the beta-globin gene that leads to polymerization of the sickle hemoglobin protein (HbS). In sickle cell disease, the red blood cells are misshapen in a sickle shape instead of a typical disc shape. The abnormal shape causes the red blood cells (RBCs) to have shortened lifespan and to block blood flow causing anemia, pain crises, organ failure, and early death. There are an estimated 100,000 people in the United States currently living with sickle cell disease. Higher levels of fetal hemoglobin (HbF) inhibit HbS polymerization, thus reducing the clinical manifestation of RBCs sickling.

​

About Beta Thalassemia

Beta thalassemia is an inherited blood disorder caused by mutations that reduce or abrogate beta globin gene expression. Insufficient beta globin production leads to ineffective red blood cell production, chronic hemolytic anemia, compensatory extramedullary hematopoiesis (creation of blood cells outside of the bone marrow), and requirement for regular blood transfusion support in patients with transfusion-dependent beta thalassemia (TDT). TDT is the most severe form of beta thalassemia, and chronic red blood cell transfusions are complicated by iron overload leading to organ dysfunction and failure. It is estimated that there are approximately 1,000 people in the United States currently living with transfusion-dependent beta thalassemia. Higher levels of fetal hemoglobin (HbF) ameliorate anemia thereby reducing the need for regular red blood cell transfusions.

​

About EDIT-301

EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). EDIT-301 consists of patient-derived CD34+ hematopoietic stem and progenitor cells edited at the gamma globin gene (HBG1 and HBG2) promoters, where naturally occurring fetal hemoglobin (HbF) inducing mutations reside, by a highly specific and efficient proprietary engineered AsCas12a nuclease. Red blood cells derived from EDIT-301 CD34+ cells demonstrate a sustained increase in fetal hemoglobin production, which has the potential to provide a one-time, durable treatment benefit for people living with severe SCD and TDT.

​

About RUBY

The RUBY trial is a single-arm, open-label, multi-center Phase 1/2 study designed to assess the safety and efficacy of a single administration of EDIT-301 in patients with severe sickle cell disease. Additional details are available on www.clinicaltrials.gov (NCT# 04853576).

​

About EDITHAL

The EDITHAL trial is a single-arm, open label, multi-center Phase 1/2 study designed to assess the safety and efficacy of a single administration of EDIT-301 in patients with transfusion-dependent beta thalassemia. Additional details are available on www.clinicaltrials.gov (NCT# 05444894).

​

​

​

About Editas Medicine

As a clinical-stage genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

​

Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s plans to continue development of EDIT-301 and share further clinical updates in 2023, and its belief about EDIT-301’s potential for clinical differentiation. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials, including the RUBY trial, and clinical development of the Company’s product candidates, including EDIT-301; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

​

​

​

###

​

​

​

Media and Investor Contact:

Cristi Barnett

(617) 401-0113

cristi.barnett@editasmed.com

ir@editasmed.com

 GRAPHIC 3 edit-20230609xex99d1001.jpg GRAPHIC begin 644 edit-20230609xex99d1001.jpg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end EX-101.SCH 4 edit-20230609.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 edit-20230609_lab.xml EX-101.LAB EX-101.PRE 6 edit-20230609_pre.xml EX-101.PRE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Jun. 09, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 09, 2023
Securities Act File Number 001-37687
Entity Registrant Name Editas Medicine, Inc.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-4097528
Entity Address, Address Line One 11 Hurley Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02141
City Area Code 617
Local Phone Number 401-9000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol EDIT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001650664
Amendment Flag false
XML 8 R2.htm IDEA: XBRL DOCUMENT v3.23.1
N-2
Jun. 09, 2023
Cover [Abstract]  
Entity Central Index Key 0001650664
Amendment Flag false
Securities Act File Number 001-37687
Document Type 8-K
Entity Registrant Name Editas Medicine, Inc.
Entity Address, Address Line One 11 Hurley Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02141
City Area Code 617
Local Phone Number 401-9000
Entity Emerging Growth Company false
XML 9 edit-20230609x8k_htm.xml IDEA: XBRL DOCUMENT 0001650664 2023-06-09 2023-06-09 0001650664 false 8-K 2023-06-09 Editas Medicine, Inc. DE 001-37687 46-4097528 11 Hurley Street Cambridge MA 02141 617 401-9000 false false false false Common Stock, $0.0001 par value per share EDIT NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995470 - Disclosure - N-2 Sheet http://xbrl.sec.gov/cef/role/N2 N-2 Notes 2 false false All Reports Book All Reports edit-20230609x8k.htm edit-20230609.xsd edit-20230609_lab.xml edit-20230609_pre.xml edit-20230609xex99d1.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "edit-20230609x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "edit-20230609x8k.htm" ] }, "labelLink": { "local": [ "edit-20230609_lab.xml" ] }, "presentationLink": { "local": [ "edit-20230609_pre.xml" ] }, "schema": { "local": [ "edit-20230609.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/2006/xbrldi-2006.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/cef/2022/cef-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022_lab.xsd" ] } }, "elementCount": 199, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "edit", "nsuri": "http://www.editasmedicine.com/20230609", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "edit-20230609x8k.htm", "contextRef": "Duration_6_9_2023_To_6_9_2023_LFVNYrQ0H0W-TC4gYdQHdA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "edit-20230609x8k.htm", "contextRef": "Duration_6_9_2023_To_6_9_2023_LFVNYrQ0H0W-TC4gYdQHdA", "decimals": null, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "edit-20230609x8k.htm", "contextRef": "Duration_6_9_2023_To_6_9_2023_LFVNYrQ0H0W-TC4gYdQHdA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityFileNumber", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995470 - Disclosure - N-2", "menuCat": "Notes", "order": "2", "role": "http://xbrl.sec.gov/cef/role/N2", "shortName": "N-2", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 0, "tag": { "cef_AcquiredFundFeesAndExpensesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses, Note [Text Block]" } } }, "localname": "AcquiredFundFeesAndExpensesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AcquiredFundFeesAndExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses [Percent]" } } }, "localname": "AcquiredFundFeesAndExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AcquiredFundFeesEstimatedNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees Estimated, Note [Text Block]" } } }, "localname": "AcquiredFundFeesEstimatedNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AcquiredFundIncentiveAllocationNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Incentive Allocation, Note [Text Block]" } } }, "localname": "AcquiredFundIncentiveAllocationNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Total Annual Expenses, Note [Text Block]" } } }, "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AllRisksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Risks:" } } }, "localname": "AllRisksMember", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "cef_AllSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Securities:" } } }, "localname": "AllSecuritiesMember", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "cef_AnnualCoverageReturnRatePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Coverage Return Rate [Percent]" } } }, "localname": "AnnualCoverageReturnRatePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AnnualDividendPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment" } } }, "localname": "AnnualDividendPayment", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_AnnualDividendPaymentCurrent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Current" } } }, "localname": "AnnualDividendPaymentCurrent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_AnnualDividendPaymentInitial": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Initial" } } }, "localname": "AnnualDividendPaymentInitial", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_AnnualExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Expenses [Table Text Block]" } } }, "localname": "AnnualExpensesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AnnualInterestRateCurrentPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Current [Percent]" } } }, "localname": "AnnualInterestRateCurrentPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AnnualInterestRateInitialPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Initial [Percent]" } } }, "localname": "AnnualInterestRateInitialPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AnnualInterestRatePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Interest Rate [Percent]" } } }, "localname": "AnnualInterestRatePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_BasisOfTransactionFeesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Transaction Fees, Note [Text Block]" } } }, "localname": "BasisOfTransactionFeesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_BdcFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BDC File Number" } } }, "localname": "BdcFileNumber", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "cef_BusinessDevelopmentCompanyFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Development Company [Flag]" } } }, "localname": "BusinessDevelopmentCompanyFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]" } } }, "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_CapitalStockTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Stock [Table Text Block]" } } }, "localname": "CapitalStockTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_DistributionServicingFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Distribution/Servicing Fees [Percent]" } } }, "localname": "DistributionServicingFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_DistributionsMayReducePrincipalTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Distributions May Reduce Principal [Text Block]" } } }, "localname": "DistributionsMayReducePrincipalTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_DividendAndInterestExpensesOnShortSalesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend and Interest Expenses on Short Sales [Percent]" } } }, "localname": "DividendAndInterestExpensesOnShortSalesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_DividendExpenseOnPreferredSharesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend Expenses on Preferred Shares [Percent]" } } }, "localname": "DividendExpenseOnPreferredSharesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_DividendReinvestmentAndCashPurchaseFees": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend Reinvestment and Cash Purchase Fees" } } }, "localname": "DividendReinvestmentAndCashPurchaseFees", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_EffectsOfLeveragePurposeTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effects of Leverage, Purpose [Text Block]" } } }, "localname": "EffectsOfLeveragePurposeTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_EffectsOfLeverageTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Table Text Block]" } } }, "localname": "EffectsOfLeverageTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_EffectsOfLeverageTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Text Block]" } } }, "localname": "EffectsOfLeverageTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ExpenseExampleTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example [Table Text Block]" } } }, "localname": "ExpenseExampleTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ExpenseExampleYear01": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Year 01" } } }, "localname": "ExpenseExampleYear01", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_ExpenseExampleYears1to10": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 10" } } }, "localname": "ExpenseExampleYears1to10", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_ExpenseExampleYears1to3": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 3" } } }, "localname": "ExpenseExampleYears1to3", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_ExpenseExampleYears1to5": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 5" } } }, "localname": "ExpenseExampleYears1to5", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_FeeTableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fee Table [Abstract]" } } }, "localname": "FeeTableAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_FinancialHighlightsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Highlights [Abstract]" } } }, "localname": "FinancialHighlightsAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_GeneralDescriptionOfRegistrantAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General Description of Registrant [Abstract]" } } }, "localname": "GeneralDescriptionOfRegistrantAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_HighestPriceOrBid": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Highest Price or Bid" } } }, "localname": "HighestPriceOrBid", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_HighestPriceOrBidNav": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, NAV" } } }, "localname": "HighestPriceOrBidNav", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_HighestPriceOrBidPremiumDiscountToNavPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "localname": "HighestPriceOrBidPremiumDiscountToNavPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveAllocationMaximumPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Allocation Maximum [Percent]" } } }, "localname": "IncentiveAllocationMaximumPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveAllocationMinimumPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Allocation Minimum [Percent]" } } }, "localname": "IncentiveAllocationMinimumPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveAllocationPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Allocation [Percent]" } } }, "localname": "IncentiveAllocationPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Fees [Percent]" } } }, "localname": "IncentiveFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_InterestExpensesOnBorrowingsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Expenses on Borrowings [Percent]" } } }, "localname": "InterestExpensesOnBorrowingsPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IntervalFundFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interval Fund [Flag]" } } }, "localname": "IntervalFundFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_InvestmentObjectivesAndPracticesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Objectives and Practices [Text Block]" } } }, "localname": "InvestmentObjectivesAndPracticesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LatestNav": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latest NAV" } } }, "localname": "LatestNav", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LatestPremiumDiscountToNavPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latest Premium (Discount) to NAV [Percent]" } } }, "localname": "LatestPremiumDiscountToNavPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_LatestSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latest Share Price" } } }, "localname": "LatestSharePrice", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LoanServicingFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Servicing Fees [Percent]" } } }, "localname": "LoanServicingFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_LongTermDebtDividendsAndCovenantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Dividends and Covenants [Text Block]" } } }, "localname": "LongTermDebtDividendsAndCovenantsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Issuance and Substitution [Text Block]" } } }, "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Principal" } } }, "localname": "LongTermDebtPrincipal", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]" } } }, "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtStructuringTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Structuring [Text Block]" } } }, "localname": "LongTermDebtStructuringTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt [Table Text Block]" } } }, "localname": "LongTermDebtTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Title [Text Block]" } } }, "localname": "LongTermDebtTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LowestPriceOrBid": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid" } } }, "localname": "LowestPriceOrBid", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LowestPriceOrBidNav": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, NAV" } } }, "localname": "LowestPriceOrBidNav", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LowestPriceOrBidPremiumDiscountToNavPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "localname": "LowestPriceOrBidPremiumDiscountToNavPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Management Fee not based on Net Assets, Note [Text Block]" } } }, "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ManagementFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Management Fees [Percent]" } } }, "localname": "ManagementFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_NetExpenseOverAssetsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Expense over Assets [Percent]" } } }, "localname": "NetExpenseOverAssetsPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_NewCefOrBdcRegistrantFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "New CEF or BDC Registrant [Flag]" } } }, "localname": "NewCefOrBdcRegistrantFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_NoPublicTradingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "No Public Trading [Text Block]" } } }, "localname": "NoPublicTradingTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_NoTradingHistoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "No Trading History [Text Block]" } } }, "localname": "NoTradingHistoryTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherAnnualExpense1Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": 1.0, "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Annual Expense 1 [Percent]" } } }, "localname": "OtherAnnualExpense1Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherAnnualExpense2Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": 2.0, "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Annual Expense 2 [Percent]" } } }, "localname": "OtherAnnualExpense2Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherAnnualExpense3Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": 3.0, "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Annual Expense 3 [Percent]" } } }, "localname": "OtherAnnualExpense3Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherAnnualExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Abstract]" } } }, "localname": "OtherAnnualExpensesAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_OtherAnnualExpensesPercent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Percent]" } } }, "localname": "OtherAnnualExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherExpensesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Expenses, Note [Text Block]" } } }, "localname": "OtherExpensesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherFeederFundExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Feeder Fund Expenses [Percent]" } } }, "localname": "OtherFeederFundExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherMasterFundExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Master Fund Expenses [Percent]" } } }, "localname": "OtherMasterFundExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Securities [Table Text Block]" } } }, "localname": "OtherSecuritiesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherSecurityDescriptionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Security, Description [Text Block]" } } }, "localname": "OtherSecurityDescriptionTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherSecurityTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Security, Title [Text Block]" } } }, "localname": "OtherSecurityTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherTransactionExpense1Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": 1.0, "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expense 1 [Percent]" } } }, "localname": "OtherTransactionExpense1Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionExpense2Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": 2.0, "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expense 2 [Percent]" } } }, "localname": "OtherTransactionExpense2Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionExpense3Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": 3.0, "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expense 3 [Percent]" } } }, "localname": "OtherTransactionExpense3Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Abstract]" } } }, "localname": "OtherTransactionExpensesAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_OtherTransactionExpensesPercent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Percent]" } } }, "localname": "OtherTransactionExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionFeesBasisMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum" } } }, "localname": "OtherTransactionFeesBasisMaximum", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_OtherTransactionFeesBasisMaximumPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum [Percent]" } } }, "localname": "OtherTransactionFeesBasisMaximumPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionFeesBasisNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Note [Text Block]" } } }, "localname": "OtherTransactionFeesBasisNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherTransactionFeesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees, Note [Text Block]" } } }, "localname": "OtherTransactionFeesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OutstandingSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Securities [Table Text Block]" } } }, "localname": "OutstandingSecuritiesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OutstandingSecurityAuthorizedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Authorized [Shares]" } } }, "localname": "OutstandingSecurityAuthorizedShares", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sharesItemType" }, "cef_OutstandingSecurityHeldShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Held [Shares]" } } }, "localname": "OutstandingSecurityHeldShares", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sharesItemType" }, "cef_OutstandingSecurityNotHeldShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Not Held [Shares]" } } }, "localname": "OutstandingSecurityNotHeldShares", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sharesItemType" }, "cef_OutstandingSecurityTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Title [Text Block]" } } }, "localname": "OutstandingSecurityTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_PreferredStockRestrictionsArrearageTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Arrearage [Text Block]" } } }, "localname": "PreferredStockRestrictionsArrearageTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_PreferredStockRestrictionsOtherTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Other [Text Block]" } } }, "localname": "PreferredStockRestrictionsOtherTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_PrimaryShelfFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Primary Shelf [Flag]" } } }, "localname": "PrimaryShelfFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_PrimaryShelfQualifiedFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Primary Shelf Qualified [Flag]" } } }, "localname": "PrimaryShelfQualifiedFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_ProspectusLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prospectus [Line Items]" } } }, "localname": "ProspectusLineItems", "nsuri": "http://xbrl.sec.gov/cef/2022", "xbrltype": "stringItemType" }, "cef_ProspectusTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prospectus:" } } }, "localname": "ProspectusTable", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_PurposeOfFeeTableNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purpose of Fee Table , Note [Text Block]" } } }, "localname": "PurposeOfFeeTableNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RegisteredClosedEndFundFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Registered Closed-End Fund [Flag]" } } }, "localname": "RegisteredClosedEndFundFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_ReturnAtMinusFivePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Minus Five [Percent]" } } }, "localname": "ReturnAtMinusFivePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtMinusTenPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Minus Ten [Percent]" } } }, "localname": "ReturnAtMinusTenPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtPlusFivePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Plus Five [Percent]" } } }, "localname": "ReturnAtPlusFivePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtPlusTenPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Plus Ten [Percent]" } } }, "localname": "ReturnAtPlusTenPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtZeroPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Zero [Percent]" } } }, "localname": "ReturnAtZeroPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_RightsLimitedByOtherSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights Limited by Other Securities [Text Block]" } } }, "localname": "RightsLimitedByOtherSecuritiesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights Subject to Other than Majority Vote [Text Block]" } } }, "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RiskAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk [Axis]" } } }, "localname": "RiskAxis", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_RiskFactorsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk Factors [Table Text Block]" } } }, "localname": "RiskFactorsTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RiskTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk [Text Block]" } } }, "localname": "RiskTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SalesLoadPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sales Load [Percent]" } } }, "localname": "SalesLoadPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_SecurityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security [Axis]" } } }, "localname": "SecurityAxis", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_SecurityDividendsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Dividends [Text Block]" } } }, "localname": "SecurityDividendsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Liabilities [Text Block]" } } }, "localname": "SecurityLiabilitiesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityLiquidationRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Liquidation Rights [Text Block]" } } }, "localname": "SecurityLiquidationRightsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityObligationsOfOwnershipTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Obligations of Ownership [Text Block]" } } }, "localname": "SecurityObligationsOfOwnershipTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityPreemptiveAndOtherRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Preemptive and Other Rights [Text Block]" } } }, "localname": "SecurityPreemptiveAndOtherRightsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Title [Text Block]" } } }, "localname": "SecurityTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityVotingRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Voting Rights [Text Block]" } } }, "localname": "SecurityVotingRightsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Amount" } } }, "localname": "SeniorSecuritiesAmount", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_SeniorSecuritiesAverageMarketValuePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Average Market Value per Unit" } } }, "localname": "SeniorSecuritiesAverageMarketValuePerUnit", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Averaging Method, Note [Text Block]" } } }, "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesCoveragePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Coverage per Unit" } } }, "localname": "SeniorSecuritiesCoveragePerUnit", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_SeniorSecuritiesHeadingsNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Headings, Note [Text Block]" } } }, "localname": "SeniorSecuritiesHeadingsNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Annualized, Note [Text Block]" } } }, "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Audited, Note [Text Block]" } } }, "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Involuntary Liquidating Preference per Unit" } } }, "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_SeniorSecuritiesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities, Note [Text Block]" } } }, "localname": "SeniorSecuritiesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities [Table Text Block]" } } }, "localname": "SeniorSecuritiesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SharePriceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Price [Table Text Block]" } } }, "localname": "SharePriceTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SharePricesNotActualTransactionsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Prices Not Actual Transactions [Text Block]" } } }, "localname": "SharePricesNotActualTransactionsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ShareholderTransactionExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Transaction Expenses [Table Text Block]" } } }, "localname": "ShareholderTransactionExpensesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_TotalAnnualExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Annual Expenses [Percent]" } } }, "localname": "TotalAnnualExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_UnderwritersCompensationPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Underwriters Compensation [Percent]" } } }, "localname": "UnderwritersCompensationPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_WaiversAndReimbursementsOfFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Waivers and Reimbursements of Fees [Percent]" } } }, "localname": "WaiversAndReimbursementsOfFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_WarrantsOrRightsCalledAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Amount" } } }, "localname": "WarrantsOrRightsCalledAmount", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_WarrantsOrRightsCalledPeriodDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Period [Date]" } } }, "localname": "WarrantsOrRightsCalledPeriodDate", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateItemType" }, "cef_WarrantsOrRightsCalledTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Title" } } }, "localname": "WarrantsOrRightsCalledTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_WarrantsOrRightsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Exercise Price" } } }, "localname": "WarrantsOrRightsExercisePrice", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "dei_AdditionalSecurities462b": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "localname": "AdditionalSecurities462b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_AdditionalSecurities462bFileNumber": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "localname": "AdditionalSecurities462bFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_AdditionalSecuritiesEffective413b": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "localname": "AdditionalSecuritiesEffective413b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings.", "label": "Approximate Date of Commencement of Proposed Sale to Public" } } }, "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateOrAsapItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r7", "r8" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "dei_DelayedOrContinuousOffering": { "auth_ref": [ "r9", "r10", "r14" ], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "localname": "DelayedOrContinuousOffering", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_DividendOrInterestReinvestmentPlanOnly": { "auth_ref": [ "r9", "r10", "r14" ], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "localname": "DividendOrInterestReinvestmentPlanOnly", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "submissionTypeItemType" }, "dei_EffectiveAfter60Days486a": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "localname": "EffectiveAfter60Days486a", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveOnDate486a": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "localname": "EffectiveOnDate486a", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateItemType" }, "dei_EffectiveOnDate486b": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "localname": "EffectiveOnDate486b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateItemType" }, "dei_EffectiveOnSetDate486a": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "localname": "EffectiveOnSetDate486a", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveOnSetDate486b": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "localname": "EffectiveOnSetDate486b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveUponFiling462e": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "localname": "EffectiveUponFiling462e", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveUponFiling486b": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "localname": "EffectiveUponFiling486b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveWhenDeclaredSection8c": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "localname": "EffectiveWhenDeclaredSection8c", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInvCompanyType": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product).", "label": "Entity Inv Company Type" } } }, "localname": "EntityInvCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "invCompanyType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "yesNoItemType" }, "dei_ExhibitsOnly462d": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "localname": "ExhibitsOnly462d", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_ExhibitsOnly462dFileNumber": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "localname": "ExhibitsOnly462dFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_InvestmentCompanyActFileNumber": { "auth_ref": [ "r10", "r11", "r12", "r13" ], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "localname": "InvestmentCompanyActFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_InvestmentCompanyActRegistration": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "localname": "InvestmentCompanyActRegistration", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_InvestmentCompanyRegistrationAmendment": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "localname": "InvestmentCompanyRegistrationAmendment", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "localname": "InvestmentCompanyRegistrationAmendmentNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sequenceNumberItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_NewEffectiveDateForPreviousFiling": { "auth_ref": [ "r10", "r11", "r12", "r13" ], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "localname": "NewEffectiveDateForPreviousFiling", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_NoSubstantiveChanges462c": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "localname": "NoSubstantiveChanges462c", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_NoSubstantiveChanges462cFileNumber": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "localname": "NoSubstantiveChanges462cFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_PostEffectiveAmendment": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "localname": "PostEffectiveAmendment", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_PostEffectiveAmendmentNumber": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective.", "label": "Post-Effective Amendment Number" } } }, "localname": "PostEffectiveAmendmentNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sequenceNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreEffectiveAmendment": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "localname": "PreEffectiveAmendment", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_PreEffectiveAmendmentNumber": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective.", "label": "Pre-Effective Amendment Number" } } }, "localname": "PreEffectiveAmendmentNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sequenceNumberItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Form N-2", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form N-3", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form N-4", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form N-6", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form S-3", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Investment Company Act", "Number": "270", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "313", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "413", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r20": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r21": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r22": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r23": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "e", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r24": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "486", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r25": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "486", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r26": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r27": { "Name": "Securities Act", "Publisher": "SEC", "Section": "8", "Subsection": "c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Form F-3", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001558370-23-010931-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-010931-xbrl.zip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end